Induction of the interleukin-2/15 receptor β-chain by the EWS–WT1 translocation product

[1]  J. Herman,et al.  SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity , 2001, Nature Genetics.

[2]  D. Haber,et al.  Wilms tumor and the WT1 gene. , 2001, Experimental cell research.

[3]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[4]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[5]  R. Greil,et al.  Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. , 2000, Blood.

[6]  P. Sorensen,et al.  Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein , 1999, Nature Genetics.

[7]  F. Magrangeas,et al.  Natural Splicing of Exon 2 of Human Interleukin-15 Receptor α-Chain mRNA Results in a Shortened Form with a Distinct Pattern of Expression* , 1999, The Journal of Biological Chemistry.

[8]  W. Gerald,et al.  The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin , 1999, Cell.

[9]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[10]  C. Y. Wang,et al.  WT1 modulates apoptosis by transcriptionally upregulating the bcl‐2 proto‐oncogene , 1999, The EMBO journal.

[11]  A. Waage,et al.  Interleukin‐15 blocks apoptosis and induces proliferation of the human myeloma cell line OH‐2 and freshly isolated myeloma cells , 1999, British journal of haematology.

[12]  D. Frank,et al.  STAT Signaling in the Pathogenesis and Treatment of Cancer , 1999, Molecular medicine.

[13]  P. Lollini,et al.  Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. , 1998, British Journal of Cancer.

[14]  Erica A Golemis,et al.  Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II , 1998, Oncogene.

[15]  R. Dummer,et al.  Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. , 1998, Blood.

[16]  J. Ritz,et al.  IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops , 1998, Oncogene.

[17]  J. Pelletier,et al.  The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties , 1998, Oncogene.

[18]  T. Whiteside,et al.  Molecular analysis of the IL-2 receptor β chain gene expressed in human tumor cells , 1998, Oncogene.

[19]  Olivier Delattre,et al.  EWS, but Not EWS-FLI-1, Is Associated with Both TFIID and RNA Polymerase II: Interactions between Two Members of the TET Family, EWS and hTAFII68, and Subunits of TFIID and RNA Polymerase II Complexes , 1998, Molecular and Cellular Biology.

[20]  J. Pelletier,et al.  The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct , 1998, Oncogene.

[21]  W. Gerald,et al.  The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour , 1997, Nature Genetics.

[22]  S. Pileri,et al.  Antigen retrieval techniques in immunohistochemistry: comparison of different methods , 1997, The Journal of pathology.

[23]  S. Ferrini,et al.  Role of interleukin (IL)-2 and IL‐15 in the tumour progression of a melanoma cell line MELP, derived from an IL‐2 progressor patient , 1997, Melanoma research.

[24]  Marcienne M Wright,et al.  EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic , 1997, Nature Genetics.

[25]  W. Leonard,et al.  The immediate-early gene product Egr-1 regulates the human interleukin-2 receptor beta-chain promoter through noncanonical Egr and Sp1 binding sites , 1997, Molecular and cellular biology.

[26]  N. Wernert.  The multiple roles of tumour stroma , 1997, Virchows Archiv.

[27]  Frank Cuttitta,et al.  Adrenomedullin Expression in Human Tumor Cell Lines ITS POTENTIAL ROLE AS AN AUTOCRINE GROWTH FACTOR* , 1996, The Journal of Biological Chemistry.

[28]  H. Werner,et al.  The IGF-I Receptor Gene Promoter Is a Molecular Target for the Ewing's Sarcoma-Wilms' Tumor 1 Fusion Protein* , 1996, The Journal of Biological Chemistry.

[29]  J. Licht,et al.  The WT1 Wilms' tumor suppressor gene: how much do we really know? , 1996, Biochimica et biophysica acta.

[30]  R. Dubose,et al.  Identification and cloning of a novel IL‐15 binding protein that is structurally related to the alpha chain of the IL‐2 receptor. , 1995, The EMBO journal.

[31]  T. Taniguchi.  Cytokine signaling through nonreceptor protein tyrosine kinases. , 1995, Science.

[32]  D. Housman,et al.  Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product , 1995, Molecular and cellular biology.

[33]  W. Gerald,et al.  Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[35]  V. Fung,et al.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. , 1994, Science.

[36]  C. Denny,et al.  The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1 , 1993, Molecular and cellular biology.

[37]  N. Bhat,et al.  Characterization of the human interleukin-2 receptor beta-chain gene promoter: regulation of promoter activity by ets gene products , 1993, Molecular and cellular biology.

[38]  David Housman,et al.  WT-1 is required for early kidney development , 1993, Cell.

[39]  W. Gerald,et al.  Intra‐abdominal Desmoplastic Small Round‐Cell Tumor: Report of 19 Cases of a Distinctive Type of High‐Grade Polyphenotypic Malignancy Affecting Young Individuals , 1991, The American journal of surgical pathology.

[40]  T. Curran,et al.  Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. , 1990, Science.

[41]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[42]  M. Caligiuri,et al.  Interleukin 15: biology and relevance to human disease. , 2001, Blood.

[43]  W. Gerald,et al.  Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  T. Waldmann,et al.  The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. , 1999, Annual review of immunology.

[45]  T. Taniguchi,et al.  The IL-2 receptor complex: its structure, function, and target genes. , 1993, Annual review of immunology.